【摘要】 为研究HDAC₂,P53,P21和Ki-67在卵巢癌中的表达变化,并探讨其临床价值。方法为采用免疫组化组织芯片（TMA）检测95例卵巢肿瘤患者（49例卵巢癌、13例交界性肿瘤、33例良性肿瘤）,分别检测卵巢肿瘤中的HDAC₂,P53,P21,Ki-67的表达,并观察与患者5年生存率的关系。结果:与良性肿瘤组织相比,卵巢癌组织中HDAC₂,P53,P21和Ki-67的表达明显增加（p<0.05）。临床分期高的卵巢癌患者Ki-67表达呈上升趋势,5年生存率与淋巴结转移及复发呈正相关（p<0.05）。结论:HDAC₂,P53,P21和Ki-67在卵巢癌的发生、发展中起重要作用,其中Ki-67还可作为判断患者预后的指标之一。更多还原

【Abstract】 Objective:To study the expression changes of HDAC₂,P53,P21 and Ki-67 in ovarian cancer and to explore their clinical value.Methods:95 cases of ovarian tumor were detected by immunohistochemical tissue microarray（TMA）,including 49 cases of ovarian cancer,13 cases of borderline tumor and 33 cases of benign tumor.The expressions of HDAC₂,P53,P21 and Ki-67 in 95 ovarian tumors were detected,and their relationship with 5-year ovarian cancer survival rate was observed.Results:compared with benign tumor tissues,HDAC₂,P53,P21 and Ki-67 expressions were significantly increased in malignant tumor tissues.The 5-year survival rate of the patients with increased Ki-67 expression was positively correlated with lymph node metastasis and recurrence（p<0.05）.Conclusion:the expressions of HDAC₂,P53,P21 and Ki-67 are increased in ovarian cancer,all of which play an important role in the occurrence and development of ovarian cancer,and Ki-67 can be used as one of the indicators to determine the prognosis of patients.更多还原